Expand ARQT Menu
ARQT MENU

ARQT Latest Press Releases

-- February 5, 2026 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- February 2, 2026 --

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis Globe Newswire 8:00 AM

-- January 26, 2026 --

Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa Globe Newswire 8:00 AM

-- January 22, 2026 --

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference Globe Newswire 4:00 PM

-- January 21, 2026 --

Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions Globe Newswire 8:00 AM

-- January 12, 2026 --

Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones Globe Newswire 8:00 AM

-- December 8, 2025 --

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri Globe Newswire 4:00 PM

-- November 17, 2025 --

FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 Globe Newswire 8:00 AM

-- November 13, 2025 --

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis Globe Newswire 8:00 AM

-- November 7, 2025 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- November 4, 2025 --

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology Globe Newswire 8:00 AM

-- October 30, 2025 --

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments Globe Newswire 9:15 AM
Arcutis Launches ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 Globe Newswire 8:00 AM

-- October 28, 2025 --

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results Globe Newswire 8:30 AM

-- October 27, 2025 --

Arcutis to Present at Upcoming Investor Conferences Globe Newswire 4:00 PM

-- October 24, 2025 --

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference Globe Newswire 8:00 AM

-- October 6, 2025 --

FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 Globe Newswire 8:00 AM

-- October 3, 2025 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- September 29, 2025 --

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 Globe Newswire 4:00 PM

-- September 17, 2025 --

Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress Globe Newswire 4:00 AM

-- September 16, 2025 --

Allure Magazine Honors Arcutis' ZORYVE (roflumilast) with Prestigious Best of Beauty Breakthrough Award Globe Newswire 9:00 AM
Market Data Delayed 15 Minutes